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Abstract
Background: Multiple sclerosis (MS) is considered an autoimmune disease of the central nervous system and
therapeutic inhibition of leukocyte migration with natalizumab, an anti-alpha4 integrin antibody, is highly effective
in patients with MS. Recent studies performed in experimental animal models with relevance to human disease
suggested a key role for blood-brain barrier damage and leukocyte trafficking mechanisms also in the
pathogenesis of epilepsy. In addition, vascular alterations and increased leukocyte accumulation into the brain were
recently documented in patients with refractory epilepsy independently on the disease etiology.
Case report: Here we describe the clinical course of a 24-year-old patient with MS in whom abrupt tonic-clonic
generalized seizures manifested at disease onset. Although MS had a more favorable course, treatment with
glatiramer acetate and antiepileptic drugs for 7 years had no control on seizure generation and the patient
developed severe refractory epilepsy. Interestingly, generalized seizures preceded new MS relapses suggesting that
seizure activity may contribute to MS worsening creating a positive feedback loop between the two disease
conditions. Notably, treatment with natalizumab for 12 months improved MS condition and led to a dramatic
reduction of seizures.
Conclusion: Our case report suggests that inhibition of leukocyte adhesion may represent a new potential
therapeutic approach in epilepsy and complement the traditional therapy with anti-epileptic drugs.
Background
Multiple sclerosis (MS) is considered a T cell-mediated
autoimmune disease of the central nervous system
(CNS) with a complex genetic background [1]. It is
accepted that blood-brain barrier (BBB) breakdown and
T cells migration across BBB initiate an immune
response against CNS myelin antigens and contribute to
disease pathogenesis [2,3]. In addition, degeneration
including loss of axons, diffuse damage to normal
appearing white matter and involvement of deep and
cortical gray matter contribute substantially to the dis-
ability progression [1]. Clinically, the focal myelin and
neuronal destruction leads to a variety of relapsing-
remitting symptoms, which later in the course may
become persistent or progressive [4].
Seizures can occur in MS patients and the risk of epi-
lepsy seems to be three-times higher in patients with
MS than in the general population [5]. Seizures can be
the presenting symptom of MS but have been observed
in relapsing-remitting as well as in secondary or primary
progressive MS. β-interferons, which are often used for
the treatment of MS, may have pro-convulsant effects
[6]. Moreover, MS symptoms can be aggravated by sev-
eral antiepileptic drugs (AEDs), which can mimic disease
activity [5]. Up to now, no clinical trials for the treat-
ment of epilepsy in MS patients have been performed
and, therefore, no clear recommendations can be given.
Recent evidence suggests that inflammation mechan-
isms play a role in the pathogenesis of epilepsy [7-12].
Moreover, recent studies performed in an experimental
mouse model of epilepsy suggested that leukocyte traf-
ficking mechanisms induce BBB damage leading to sei-
zure generation [10]. These results were supported by
studies performed in an acute viral meningitis model in
which cytotoxic T lymphocytes and massive recruitment
of monocytes and neutrophils were required for vascular
leakage and seizure-induced death [11]. Importantly,
white matter angiopathy and increased number of
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any medium, provided the original work is properly cited.CD68-positive cells and CD3-positive T cells in perivas-
cular cavities were documented in a subpopulation of
young patients with refractory epilepsy [12]. In addition,
increased number of leukocytes was observed in brain
parenchyma of epileptic patients, independently on the
disease etiology [10]. However, despite growing evidence
showing a role for leukocyte trafficking and BBB damage
in seizure generation, clinical trials with anti-adhesion
therapies have not been performed yet in patients with
epilepsy.
Current anti-inflammatory and immunosuppressive
MS-treatments include β-interferons, glatiramer acetate
(GA) and different chemotherapies. Recently, natalizu-
mab, a monoclonal antibody directed against the a4
chain of integrin VLA-4, an adhesion molecule control-
ling leukocyte adhesion to brain endothelium, was
approved by the U.S. Food and Drug Administration
and the European Medicines Agency as monotherapy
for highly active relapsing-remitting MS. Despite the
occurrence of progressive multifocal leukoencephalopa-
thy (PML) as adverse reaction, natalizumab represents
the most potent drug approved thus far for the treat-
ment of relapsing-remitting MS [13,14].
H e r ew ed e s c r i b ead r a m a t i cr e d u c t i o no fs e i z u r e s
after treatment with natalizumab in a patient with
severe refractory epilepsy and MS. For better clarity we
split the description of seizures and epilepsy from the
non-epileptic MS course.
Case presentation
The 10-years follow-up, from MS onset (October 1999) to
January 2010 is summarised on Table 1. Clinical (relapse
and EDSS) and subclinical (MRI) MS activities are indi-
cated. Epilepsy-related information concerning type, sever-
ity (status epilepticus) and frequency of seizures, type and
dose of antiepileptic drugs (AEDs) are also reported. In
the time interval 1999-2000 the patient suffered from 1
partial and 1 generalised seizure (those at disease onset) as
described below in the text. Abbreviations and symbols
are the followings: n.d. = not done; * = mild decrease in
mentation; ** = marked decrease in learning and memory;
EDSS = Kurtzke’s expanded disability status scale; VPA =
valproate; CBZ = carbamazepine; LMT = lamotrigine;
TOP = topiramate; OXC = oxcarbazepine; KEP = levetira-
cetam; GBP = gabapentin;
§ = LMT discontinued after 1
month for allergic dermatitis. Each non-epileptic MS
relapse has been treated with methyl-prednisolone 1 gr/
daily for 3-5 days without tapering-off.
MS onset and course
a) From onset (1999) to GA therapy (2002)
In October 1999, a previously healthy 24-year-old man
complained of the sudden appearance of a brainstem
syndrome (multiple oculomotor nerves involvement and
gait instability) followed, 24 hours later, by an abrupt
tonic-clonic generalized seizure. Routine laboratory
exams were normal. Family and personal history were
all negative for neuro-psychiatric, hereditary and auto-
immune diseases. MRI showed multiple supra-and infra-
tentorial T2-w hyper-intense and two Gd-enhanced T1-
w lesions. Cerebrospinal fluid (CSF) composition was
normal in protein level and cell count. Post-critical EEG
was also normal.
Differential diagnosis was made with conditions caus-
ing seizures and mimicking MS either of inflammatory
(vasculitis, sarcoidosis, systemic lupus erythematosus,
Sjögren’s syndrome, Behçet’s disease), infectious (herpes,
Lyme disease, HTLV-1, syphilis), genetic (CADASIL,
adrenoleukodystrophy, lysosomal and mitochondrial dis-
orders), metabolic (vitamin B12 deficiency, hyper-homo-
cysteinemia), and neoplastic origin (CNS lymphoma).
Anti-voltage-gated potassium channel and onconeural
antibodies for limbic encephalitis were also tested. All
investigations performed to seek for signs of these dis-
eases resulted negative. A subsequent spinal MRI per-
formed a week after disease onset showed cervical T2-w
Table 1 Clinical follow-up of the MS case from MS onset (1999) up to January 2010. Abbreviations and symbols in the
text (Case Presentation)
Year 1999-2000 2001 2002 2003 2004 2005 2006 2007 2008 2009-2010
Non-epileptic MS relapses 10 1010011 0
Brain MRI activity
(new T2 or Gd
+ lesions or both)
+ - + - - n.d. - n.d. + -
EDSS score - 0 1 1 2 2 2.5* 3* 4** 2.5*
MS therapy - - GA GA GA GA GA GA GA Natalizumab
Partial seizures 1 (onset) 1 4 4 6 8 7 8 10 4
Generalized seizures 1 (onset) 1 3 2 3 6 5 5 7 0
Status epilepticus 0 0 0001011 0
AEDs (daily dose in mg) VPA 600 VPA 1000 VPA 1000 VPA 1000 VPA 1300 VPA 1000 KEP 3000 KEP 3000 KEP 1000
CBZ 300 CBZ 800 CBZ 1200 CBZ 1400 LMT
§ OXC 2100 OXC 2400 GBP 900
TOP 250 GBP 900
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oligoclonal bands were found, which allowed a diagnosis
of laboratory-supported definite MS according to the
Poser criteria in use at that time [4]. A course of
methyl-prednisolone 1 gr/day for five days was adminis-
tered, followed by a long-term remission of all symp-
toms and signs. During 2000 and 2001 the patient did
not complain of any symptom referable to MS, except
from two seizures (see below). During 2000/2001
Kurtzke’s EDSS (expanded disability status scale) score
[15] was zero and brain MRI in 2001 was unchanged.
The patient received no treatment during this period.
b) MS course during GA treatment (2002-2008)
The first MS relapse occurred during 2002 and was
characterized by a mild cerebellar ataxia and dysmetria
(Table 1). Romberg sign was absent. A new brain MRI
showed the occurrence of new small T2-w lesions. A
short course of methyl-prednisolone 1 gr/day for three
days was administered. As β-interferons seem contrain-
dicated for their detrimental effect on seizures [6], treat-
ment with GA was started and was well tolerated till the
end of 2008. After six months of GA treatment the
EDSS score was 1 (very mild dysmetria on left hand).
The second MS relapse occurred in May 2004 and
was characterized by diplopia. Neurological examination
disclosed a mild right internuclear ophthalmoparesis
and MRI revealed the absence of new T2-w or Gd-
enhancing lesions (Table 1). A new course of methyl-
prednisolone 1 gr/day for five days was administered
and symptoms subsided in two week. After 6 months
(November 2004) the EDSS score was 2 (dysconjugated
nystagmus with diplopia and dysmetria).
The third non-epileptic MS relapse occurred three
years later (April 2007) and was characterized by urinary
urgency. MRI was not performed. At examination, a left
Babinski sign was evident together with nystagmus and
dysmetria. EDSS score was 3 (Table 1). A new course of
methyl-prednisolone 1 gr/day for five days was adminis-
tered and symptoms subsided in four weeks.
In October 2008 new clinical (right hemiparestesia)
and subclinical MRI activities emerged, showing new
T2-w lesions in both brain and spinal cord and Gd-
enhancing T1-w brain lesions (Figure 1A-D). Patient’s
reflexes were enhanced in both legs and pallesthesia was
absent in the feet. In addition memory, attention, lan-
guage, perception and problem solving were markedly
reduced, and EDSS score increased to 4. At this point,
the clinical and MRI findings indicated the need for a
new MS-therapy and natalizumab treatment was
planned to begin in 2009 after three months wash-out
of GA.
c) Effect of Natalizumab on MS course
Natalizumab was administered at a dose of 300 mg
every 4 weeks from February 2009 till January 2010 (12
months follow-up, present study). The cognitive status
improved and the EDSS score decreased to 2.5 in Janu-
ary 2010 (Table 1). He did not complain side effects of
natalizumab and the JCV detection in blood after 9
months of treatment was negative. The MRI in October
2009 showed neither Gd-enhancement nor new or
enlarging T2-w lesions (Figure 1E).
2. Epilepsy onset and course
a) Epilepsy onset
In October 1999, 24 hours after the sudden appearance
of the demyelinating brainstem syndrome the patient
presented a generalized tonic-clonic epileptic seizure
with tongue laceration and urinary incontinence. Post-
critical EEG (24 hours after seizure) was normal. No
specific treatment for seizures was initiated. Although
EDSS score was zero and brain MRI was unchanged, on
December 2001 the patient presented a second general-
ized tonic-clonic epileptic seizure, which was preceded
by a simple partial seizure of focal motor activity on the
left body part (Table 1, Figure 2A). Post-ictal EEG
showed a focus of low-amplitude slow activity over the
left fronto-temporal region. Antiepileptic therapy with
Valproate (VPA, 600 mg/day) was started.
b) Epilepsy course during GA treatment (2002-2004)
Starting from March 2002, 3 months before the first MS
relapse and initiation of GA treatment, the patient com-
plained of recurrent stereotyped disorders consisting of
different types of partial (simple and complex) seizures,
lasting less than 3 minutes and sometimes overlapping:
i) focal motor activity of the left part of the body, ii)
loss of contact with surroundings followed by drowsi-
ness, iii) gestural automatisms. Often, these episodes
were followed by secondarily generalized tonic-clonic
seizures (Figure 2A, Table 1). During 2002 increasing
doses of carbamazepine were administered, whereas
valproate daily dose was augmented to 1000 mg.
Although the AED doses were enhanced, seizure fre-
quency increased progressively even in the absence of
MRI activity (Table 1 and Figure 2A). During 2004,
despite treatment with valproate (1000 mg/day) and car-
bamazepine (1200 mg/day), the patient manifested 6
partial and 3 generalized seizures (Table 1 and Figure
2A).
c) Epilepsy worsening during GA treatment (2005-2008)
Notably, although the non-epileptic MS course was well
controlled (one relapse in 2007; MRI stable in 2006), the
epileptic condition worsened during the period 2005-
2007 (Figure 2A, Table 1). Besides an increased number
and duration (over 3 minutes) of partial and generalized
seizures, the patients also manifested focal and general-
ized convulsive status epilepticus requiring intervention
in intensive care department and treatment with intrave-
nous lorazepam, diazepam and/or phenobarbital.
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AEDs (including topiramate, levetiracetam, oxcarbaze-
pine and gabapentin) at increasing daily dosage and
often in association, as indicated on Table 1. Partial
epileptic discharges at EEG were commonly observed
(data not shown). Despite the frequent therapy changes
in dose and type of AEDs, the pharmacologic control
of seizures was clearly ineffective and the patient
was diagnosed with refractory MS-related epilepsy in
late 2006.
Figure 1 Cranial and spinal MRI before and after treatment with Natalizumab. A. Axial FLAIR (fluid attenuation inversion recovery) scan
performed on October 2008 before Natalizumab treatment showing multiple hyperintense MS lesions in the periventricular areas of both
hemisheres. B. Sagittal STIR (Short TI Inversion Recovery) sequence of spinal cord performed on October 2008, showing a high number of
hyperintense demyelinating lesions in the cervical and dorsal spinal tracts (two representative are indicated by arrows). C. Axial FLAIR scan
performed on October 2008 showing hyperintense subcortical MS lesions of both hemisheres. D. After intravenous injection of Gadolinium, an
intense contrast enhancement is shown in one subcortical lesion of the right parietal area (arrow). E. Representative axial T1-wheighted scan
(periventricular section) after intravenous injection of Gadolinium, performed on October 2009 during natalizumab treatment. Multiple
hypointense MS lesions are evident in the periventricular areas of both hemispheres (the largest is indicated by the arrow) with no Gadolinium-
enhancement. The MRI evaluation also included T2 and FLAIR scans of the whole brain. Besides the absence of contrast-enhancement, no new
or enlarging T2-FLAIR lesions were evident after natalizumab treatment (not shown).
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Page 4 of 8Figure 2 Effect of Natalizumab on seizure frequency and EEG tracks. A. Bars indicate the number of episodes of partial (yellow) and
generalized (blue) seizures along the 10-years period. After natalizumab introduction (arrow), the number (Y axis) of partial seizure dramatically
dropped from 10 to 4 (60% reduction), while generalized seizures disappeared. T-test (two-tailed 95% confidence interval) was used to test the
null hypothesis (number of seizures after the start of natalizumab is not different from the mean of the 2002-2008 period). Mean values were
6.71 ± 2.21 (95% CI 3.22-5.62) for partial seizures and 4.43 ± 1.81 (95% CI 5.24-8.17) for generalized seizures, respectively. One tailed p-values are
0.003 for partial (*) and 0.00004 for generalized (**) seizures, allowing to strongly reject the null hypothesis. B. Intercritical scalp EEG recording
(18’’ duration) of the case, performed while awake on July 2008 and showing a reactivation of a focus of sharp waves and low-amplitude slow
activity over the left fronto-temporal region, which correspond to a complex partial seizure accompanied by gestural automatisms. The patient
was on therapy with GA and on poly-AEDs treatment (oxcarbazepine 2400 mg/day, levetiracetam 3000 mg/day and gabapentin 900 mg/day). C.
Intercritical scalp EEG recording (18’’ duration) performed on June 2009 while awake, showing minimal low-amplitude slow activity over the left
fronto-temporal region. The patient was on therapy with natalizumab and on poly-AEDs treatment with levetiracetam 2000 mg/day (33%
reduction) and gabapentin 900 mg/day. Scalp EEG recording set up: PA filter 0.53 Hz; PB filter 30 Hz, amplitude 70 microvolt/cm. Electrode
placement refers to the Jasper’s 10-20 system. EKG = electrocardiogram.
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ted partial and 7 generalized seizures. In June 2008 he
was brought to the intensive care department for gener-
alized status epilepticus. A month later, an intercritical
EEG showed partial epileptic discharges (Figure 2B).
Although in October 2008 we documented a new MS
relapse, we cannot exclude a contribution of the ele-
vated AEDs daily dosage in the decline of cognitive sta-
tus at the end of 2008 [6].
d) Effect of Natalizumab on epilepsy
Natalizumab therapy was initiated in February 2009 and
till January 31, 2010 (12 months follow-up) the patient
manifested only 4 short (less than 2 minutes) complex
partial seizures (60% reduction compared to 2008).
Importantly, during natalizumab treatment we observed
no generalized seizures (100% reduction) and the
absence of status epilepticus. Intercritical EEG per-
formed in June 2009 was normal (Figure 2C). Oxcarba-
zepine was progressively discontinued, and the patient
was treated with gabapentin 900 mg/day and levetirace-
tam, which was progressively reduced (1000 mg/day).
Although there are no known interactions between nata-
lizumab and AEDs, further studies are warranted to for-
mally exclude this possibility. Overall, the results
showed a dramatic improvement of seizure activity after
12 months of treatment with natalizumab.
Discussion
Epilepsy affects between 0.5-1% of world population
and, despite medical therapy, about one third of patients
develop refractory epilepsy [16-18]. Among other fac-
tors, MS represents a risk factor for refractory epilepsy
[19]. The pathophysiology of seizures in MS remains to
be elucidated although cortical and subcortical lesions
(as in our case, Figure 1C) may reasonably explain their
increased frequency in MS [5]. Seizures can occur in
MS patients as the presenting symptom or as a relapse,
being either related or unrelated to other, non epileptic
clinical relapses [5]. In our case, seizures occurred in
both conditions as indicated on Table 1. Epileptic and
non-epileptic symptoms were concomitant at disease
onset (seizures followed ophthalmoparesis by 24 hours),
and during 2004, and 2007. In contrast, seizures
appeared to be clinically and temporally isolated in
2001, 2002, 2003, 2005, 2006 and 2008 and during the
course of natalizumab therapy.
Experimental and clinical studies have shown that
inflammation mechanisms are activated in epilepsy [7].
Proinflammatory cytokines such as IL-1β,T N F - a and
IL-6 have been shown to be overexpressed in experi-
mental models of seizures, prominently by glia [20], sug-
gesting that glia activation may contribute to vascular
inflammation in epilepsy. In addition, increased proin-
flammatory cytokines were found in the serum and CSF
in patients with epilepsy, whereas the analysis of human
brain specimens from drug-refractory epileptic patients
showed strong activation of the IL-1b/IL-1R1 system in
brain resident cells, such as in glia and neurons [21,22].
Functional interactions between cytokines and classical
neurotransmitters such as glutamate and GABA have
been also described, pointing out at novel glio-neuronal
communications in epilepsy and suggesting that cyto-
kine-mediated changes in neuronal excitability may pro-
mote seizures [20]. Innate immune mechanisms such as
complement have been also shown to be potentially
involved in epilepsy [22]. The role of innate immunity
was further supported by a recent study performed in
spontaneously epileptic mice and in human TLE show-
ing a new proconvulsant pathway involving high-mobi-
lity group box-1 (HMGB1) release from neurons and
glia and its interaction with Toll-like receptor 4 (TLR4)
[23]. TLR4 and HMGB1 blockade by pharmacologic
inhibitors or by genetic deficiency, potentially inter-
rupted glia-neuron communication and reduced seizure
generation in animal models of seizures in this study
[23].
In addition to the inflammation mechanisms described
above, recent studies performed in experimental animal
models with relevance to human disease show a role for
vascular inflammatory mechanisms and leukocyte-
endothelial adhesion in the induction of BBB leakage
and seizure generation [10,11]. BBB breakdown has
been implicated both in the induction of seizures and in
the progression to epilepsy with chronic seizure genera-
tion by exposure of neuronal cells to blood albumin and
potassium ions [9,24-26]. Moreover, inhibition of BBB
breakdown by blockade of leukocyte-endothelial interac-
tion with an anti-VLA-4 antibody has preventive as well
as therapeutic effects in a mouse model of epilepsy [10].
VLA-4 mediates adhesion of lymphocytes [27], mono-
cytes [28] and under inflammatory conditions also of
neutrophils [29], suggesting that leukocytes from innate
and adaptive immunity may both contribute to seizure
generation.
Acute seizure activity induces expression of adhesion
molecules on brain endothelium [10,30]. Importantly, it
has been recently shown that also recurrent seizures
lead to chronic expression of VCAM-1, the ligand for
VLA-4 integrin, potentially contributing to BBB perme-
ability, neuroinflammation and brain damage potentially
contributing to the evolution of chronic disease [10].
Vascular inflammation induced by each seizure (even-
tually also in the absence of concomitant infection and
autoimmunity) may allow adhesion and transmigration
of myeloid cells and activated lymphocytes, increasing
local inflammation and potentially favoring the genera-
tion of new seizures. However, whether vascular inflam-
mation, leukocyte trafficking mechanisms and BBB
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clarified in further studies.
In support to the results obtained from animal models
of epilepsy, it has been shown that BBB disruption in
patients with cerebral lymphoma induces focal motor
seizures [9]. Vascular alterations and lymphocyte accu-
mulation into the brain parenchyma were documented
in a study performed on 87 young patients with refrac-
tory epilepsy [12]. In addition, perivascular and parench-
ymal T lymphocytes with a predominance of CD8
cytotoxic cells were found in grey and white matter in
samples obtained from patients with tuberous sclerosis
complex [31]. Cells of the microglia/macrophage cell
system and scarce CD3 lymphocytes were also found to
accumulate in brain samples obtained from patients
with of TLE and hippocampal sclerosis [21]. In addition,
recent results showed increased number of leukocytes in
brain parenchyma of patients with epilepsy indepen-
dently on the disease etiology [10]. In line with these
previous data showing that leukocyte subpopulations
may accumulate in the brain of patients with epilepsy,
the results described in the present manuscript show
successful treatment of epilepsy with natalizumab in a
patient with MS. Notably, MS and epilepsy started con-
comitantly, but disease courses were relatively divergent
during a 6-year period in which MS was under relative
control with GA treatment whereas seizure frequency,
duration and severity highly increased. Interestingly,
generalized seizures preceded most of the new MS
relapses leading us to speculate that, as seizure activity
per se induces vascular inflammation [10], seizure activ-
ity may contribute to MS worsening. Thus, our results
suggest that MS contribution to epilepsy induction,
together with seizure activity potentially favoring MS
relapses, may create a positive feedback loop between
the two disease conditions.
The generalization of the remarkable effect of natalizu-
mab on refractory epilepsy observed in the present clinical
case to other more common types of epilepsy requires
further studies. In contrast to the anti-adhesion therapy
with natalizumab, a specific and sustained anti-adhesive
activity exerted by GA and steroids in the present clinical
case seems rather unlikely. In fact, GA treatment causes in
vivo changes of the cytokine secretion pattern and effector
function of GA-specific T cells but increases the migration
rate of Th2 cells and do not affect the migration of Th1
cells [32,33], whereas steroids may reduce endothelial acti-
vation in a transient and non-selective manner during its
short clinical use after MS relapses.
Conclusions
Current pharmacological treatments for epilepsy do not
address the inflammatory component of pathogenesis
highlighted by recent studies and most AED drugs aim
to depress aberrant neuronal excitation. However, non-
compliant and refractory epilepsy cases demand investi-
gation into alternative mechanisms and corresponding
treatments, and interfering with the adhesion of immune
cells to the cerebral vasculature may potentially open
new avenues for epilepsy treatment [34].
Our results indicate treatment with natalizumab as
highly effective in patients with MS and epilepsy. As no
interactions with AED drugs were described for natali-
zumab and recent clinical data show that safety may be
increased for PML associated with natalizumab therapy
[35], our results suggest that anti-adhesion therapies
such as natalizumab may complement traditional thera-
pies, and might be useful in treating refractory epilepsy
and epilepsy following MS or inflammatory inciting
events such as trauma, stroke and infections.
Taking into account our current understanding of the
pathogenesis of seizures and epilepsy and the emerging
key role of inflammation mechanisms in epilepsy, our
data suggest a more general application of natalizumab
and anti-adhesion therapy in other types of epilepsy.
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